Intermittent Versus Continuous Infusion Meropenem in Cystic Fibrosis

NCT02048163 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2016-02-08

No results posted yet for this study

Summary

The purpose of this study is to compare the incidence of nausea and vomiting following short intermittent versus prolonged intermittent infusion of meropenem.

Conditions

Sponsors & Collaborators

  • Dayton Children's Hospital

    lead OTHER

Principal Investigators

  • Pat Christoff, PharmD · Dayton Children's Hospital

Eligibility

Min Age
7 Years
Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2015-08-31
Completion
2015-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02048163 on ClinicalTrials.gov